tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

CollPlant Biotechnologies Announces Annual and Extraordinary General Meeting for December 2025

Story Highlights
  • CollPlant Biotechnologies will hold its annual and extraordinary general meeting on December 31, 2025.
  • Key proposals include board re-elections, auditor re-appointment, and CEO appointment as interim Chairman.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
CollPlant Biotechnologies Announces Annual and Extraordinary General Meeting for December 2025

TipRanks Black Friday Sale

The latest update is out from Collplant Holdings ( (CLGN) ).

On November 26, 2025, CollPlant Biotechnologies Ltd. announced that it will hold its annual and extraordinary general meeting of shareholders on December 31, 2025, in Tel-Aviv, Israel. The meeting will address several key proposals, including the re-election of board members, re-appointment of auditors, renewal of the compensation policy for directors and officers, and the appointment of CEO Yehiel Tal as interim Chairman of the Board. The outcomes of this meeting could influence the company’s governance and strategic direction, impacting stakeholders and potentially affecting its market position.

The most recent analyst rating on (CLGN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

Spark’s Take on CLGN Stock

According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.

Collplant Holdings’ overall stock score is primarily impacted by its poor financial performance, characterized by significant revenue and cash flow declines and negative profit margins. Technical analysis also indicates a bearish trend, while valuation metrics highlight the company’s unprofitability. These factors collectively suggest a high-risk investment without immediate signs of improvement.

To see Spark’s full report on CLGN stock, click here.

More about Collplant Holdings

CollPlant Biotechnologies Ltd. operates in the biotechnology industry, focusing on the development and commercialization of regenerative medicine products. The company is known for its innovative plant-based technology for producing recombinant human collagen, which is used in various medical applications, including tissue repair and organ manufacturing.

Average Trading Volume: 96,243

Technical Sentiment Signal: Strong Sell

Current Market Cap: $28.48M

For detailed information about CLGN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1